Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 3Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Solid Tumors 2Thrombocythemia, Essential 1Polycythemia Vera 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Glioblastoma 1Chromosome 17 deletion 1

Interventions

Cytarabine 272Cyclophosphamide 136fludarabine phosphate 127Azacitidine 117Peripheral Blood Stem Cell Transplantation 95Busulfan 93Filgrastim 80Decitabine 79fludarabine 78Mycophenolic Acid 78Idarubicin 76Etoposide 76Whole-Body Irradiation 75Daunorubicin 72Tacrolimus 71Cyclosporine 64Methotrexate 62Mitoxantrone 57Clofarabine 55Antilymphocyte Serum 55Granulocyte Colony-Stimulating Factor 51Gemtuzumab 50Melphalan 49venetoclax 48Radiotherapy 30sargramostim 28Injections 25Bortezomib 25thymoglobulin 24aldesleukin 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Myeloid, Acute × RG7388 × Clear all
NCT02670044 2022-01-03

A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

Hoffmann-La Roche

Phase 1 Completed
88 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡